Lung cancer Posts Page 2 on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

New targeted therapies have potential to improve overall survival for patients with EGFR-mutation positive NSCLC

Posted by on Aug 8, 2018 in Lung cancer | 0 comments

In a nutshell This study compared dacomitinib (PF-00299804) to gefitinib (Iressa) as a first treatment for patients with EGFR-mutation positive non-small-cell lung cancer. The authors concluded that treatment with dacomitinib provided an improved overall survival compared to gefitinib. Some background Current cancer therapy heavily...

Read More

Comparing targeted therapy to chemotherapy for patients with advanced NSCLC

Posted by on Aug 8, 2018 in Lung cancer | 0 comments

In a nutshell This trial compared the effectiveness of alectinib (Alecensa) against chemotherapy for treating patients with ALK-positive non-small-cell lung cancer that have progressed passed previous targeted therapy. The authors determined that alectinib was more effective than chemotherapy at treating this subgroup of patients. Some background Lung...

Read More

Combining therapies to treat advanced NSCLC

Posted by on Jul 14, 2018 in Lung cancer | 0 comments

In a nutshell This trial examined the effectiveness of combining the targeted therapy drug pembrolizumab (Keytruda) with chemotherapy at treating certain types of advanced non-small-cell lung cancer. The trial concluded that this combination is more beneficial than chemotherapy alone for treating this subset of patients. Some background PD-1...

Read More

ASCO 2018: Chemotherapy Side Effects & Treating Metastatic Lung Cancer

ASCO 2018: Chemotherapy Side Effects & Treating Metastatic Lung Cancer

Posted by on Jun 4, 2018 in Blog, Colorectal cancer, Lung cancer | 0 comments

The American Society of Clinical Oncology (ASCO) meets at the beginning of June each year in Chicago. It is the world’s largest oncology organization where researchers from around the world present their research findings. Here are the results of two studies presented during the first couple of days of the conference. Chemotherapy Side Effects and...

Read More

Comparing two targeted therapy drugs – is gefitinib safer than erlotinib?

Posted by on May 21, 2018 in Lung cancer | 0 comments

In a nutshell This study compared two targeted therapy drugs gefitinib (Iressa) and erlotinib (Tarceva) in terms of effectiveness and safety at treating patients with advanced non-small-cell lung cancer. They concluded gefitinib was as effective as erlotinib but with fewer toxic side effects. Some background Current and newer treatment options...

Read More

Is targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?

Posted by on Apr 21, 2018 in Lung cancer | 0 comments

In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...

Read More